Please login to the form below

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer

Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically underfunded and awareness is low, in part because of widespread misconceptions regarding the disease. This World Pancreatic Cancer Day, let’s educate ourselves so that we can all ‘Demand Better’ in the fight against the world’s toughest cancer.

Today, 15 November, marks World Pancreatic Cancer Day. This year’s focus is to ‘Demand Better’ in the fight against pancreatic cancer, pushing for more attention, more awareness and more progress to help patients fight and survive the disease [1].

The statistics for pancreatic cancer statistics make for grim reading. Patients usually only live for up to 6 months [2] and a meagre 8% of patients survive for 5 years [3]. This shocking survival rate has barely improved over the last 40 years [4] while, in the same period, we have seen vast improvements in the numbers of people surviving other cancers [5]. In spite of these statistics, funding for pancreatic cancer and disease awareness are low. Indeed, the disease receives only 3% of UK cancer research funding [6], and a patient survey showed that nearly half of patients had never even heard of the disease prior to their diagnosis [7].

There are several misconceptions that contribute to these issues and these may represent the single most significant barrier to achieving improved survival and patient experience, according to a parliamentary inquiry undertaken by the All-Party Parliamentary Group (APPG) on Pancreatic Cancer. These misconceptions were widespread, from the public through to healthcare professionals and policymakers [8].

Misconception

Reality

Pancreatic cancer is rare [8]

Although the incidence of pancreatic cancer is lower than other common cancers like breast, bowel and lung, pancreatic cancer is the 5th most common cause of all cancer deaths in the UK [8].

Pancreatic cancer affects mostly elderly, male patients [8]

The risk of pancreatic cancer does increase with age; however, nearly 35% of all diagnoses of pancreatic cancer occur in people under the age of 65. In addition, pancreatic cancer affects men and women equally [8].

Pancreatic cancer is a silent killer with indistinguishable symptoms [8]

Pancreatic cancer systems are often non‑specific; however, research shows that many people seek medical attention for these symptoms some time before diagnosis [8].

Once diagnosed, there is nothing that can be done to change the course of the disease or to offer a prolonged life of good quality [8]

Patients diagnosed in time for surgery are up to 30% more likely to survive beyond 5 years than those who are diagnosed later [6]. Even if diagnosed at an advanced stage, treatments are available that may extend life and will almost certainly improve the quality of life [8].

The APPG stated concerns that these misconceptions result in [8]:

  • Low levels of awareness of the disease
  • Low levels of awareness of the extent to which the disease represents a leading cause of cancer deaths in the UK
  • A lack of investment that is proportionate to the impact of this disease
  • A lack of urgency in ensuring that everyone affected by pancreatic cancer is diagnosed as early as possible
  • A lack of urgency in ensuring that, once diagnosed, everyone receives the most prompt and up-to-date treatment possible

Early diagnosis is key to improving survival in pancreatic cancer. Currently, only 10%–20% of people with pancreatic cancer are diagnosed when they are still eligible for resection surgery, the only potentially curative treatment for pancreatic cancer. The reasons for this are multifaceted. Poor public awareness of the symptoms of the disease is an important issue; however, there are also delays in diagnosis once a patient has sought medical attention for pancreatic cancer–related symptoms. According to Pancreatic Cancer UK’s 2015 Symptoms and Diagnosis Survey, 63% of respondents reported that they or their family member visited their GP three times or more before diagnosis, and 23% had visited seven times or more. In fact, almost half of all patients are diagnosed as an emergency in A&E, when they have begun to experience severe symptoms. At this point, it is more likely that the cancer has already spread to other parts of the body, and is therefore associated with substantially poorer survival rates than other routes of diagnosis [9].

Worryingly, even when the disease is diagnosed when still localised, surgical resection remains strikingly underutilised. One reason hypothesised for this is that patients might never be evaluated by a surgeon because of the misconception held by many primary physicians: that there is nothing that can be done to change the course of the disease. Indeed, in one analysis, only 75% of patients with localised pancreatic cancer underwent surgical evaluation. Simply maximising rates of surgical resection is one way we can make an immediate improvement in survival and impact thousands of patients [10].

Unless substantial improvements are made now, pancreatic cancer will soon overtake breast cancer and become the 4th most common cancer killer in the UK [11]. The need to raise awareness, improve investment and change our views and approaches to the diagnosis and treatment of pancreatic cancer is evident, and the onus is on everyone – the public, healthcare professionals and policymakers – to take part in these efforts.

References:

For references, please visit : https://www.porterhousemedical.com/news/world-pancreatic-cancer-day-2018-combating-misconceptions-in-pancreatic-cancer/

15th November 2018

Share

Tags

Company Details

Porterhouse Medical Group

+44 (0)118 913 9100

Contact Website

Address:
4 Windsor Square
Silver Street
Reading
RG1 2TH
United Kingdom

Latest content on this profile

Putting our mission into practice: Porterhouse Medical’s charity round-up 2018 - 2019

Porterhouse Medical Group
Creativity reaches new heights at Porterhouse Medical

Porterhouse Medical Group
Meet Porterhouse Medical at the ISMPP EU meeting 2019 in London 22 - 23 January
Porterhouse Medical’s strategic publication planning experts are participating in two events at the 2019 European Meeting of the International Society for Medical Publication Professionals, entitled: 'Scientific communications in a fast-paced world: Fighting fit for the future'.
Porterhouse Medical Group
Porterhouse Medical Group adds to its growing team of scientific and medical experts

Porterhouse Medical Group
A well-deserved promotion within Porterhouse Medical’s scientific services team

Porterhouse Medical Group
Highlights in haematologic malignancy from ASH 2018
The ASH congress is the most comprehensive haematology event of the year, over 5000 abstracts covering new developments in malignant and non-malignant haematology were presented. Here we focus on two areas of personalised medicine from the oncology setting.
Porterhouse Medical Group